Indaptus Therapeutics (NASDAQ:INDP) Releases Earnings Results

Indaptus Therapeutics (NASDAQ:INDP) posted its earnings results on Monday. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07, Zacks reports.

Indaptus Therapeutics Trading Down 1.8 %

Shares of INDP traded down $0.03 on Thursday, reaching $1.65. The company’s stock had a trading volume of 1,476 shares, compared to its average volume of 44,805. Indaptus Therapeutics has a twelve month low of $1.56 and a twelve month high of $4.08. The firm has a fifty day moving average of $2.15 and a 200-day moving average of $2.16. The stock has a market capitalization of $14.09 million, a PE ratio of -0.94 and a beta of 1.39.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Indaptus Therapeutics in a research note on Monday, June 17th.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.